TY - JOUR
T1 - Movember GAP1 PDX project
T2 - An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models
AU - Navone, Nora M.
AU - van Weerden, Wytske M.
AU - Vessella, Robert L.
AU - Williams, Elizabeth D.
AU - Wang, Yuzhuo
AU - Isaacs, John T.
AU - Nguyen, Holly M.
AU - Culig, Zoran
AU - van der Pluijm, Gabri
AU - Rentsch, Cyril A.
AU - Marques, Rute B.
AU - de Ridder, Corrina M.A.
AU - Bubendorf, Lukas
AU - Thalmann, George N.
AU - Brennen, William Nathaniel
AU - Santer, Frédéric R.
AU - Moser, Patrizia L.
AU - Shepherd, Peter
AU - Efstathiou, Eleni
AU - Xue, Hui
AU - Lin, Dong
AU - Buijs, Jeroen
AU - Bosse, Tjalling
AU - Collins, Anne
AU - Maitland, Norman
AU - Buzza, Mark
AU - Kouspou, Michelle
AU - Achtman, Ariel
AU - Taylor, Renea A.
AU - Risbridger, Gail
AU - Corey, Eva
N1 - Publisher Copyright:
© 2018 Wiley Periodicals, Inc.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Background: While it has been challenging to establish prostate cancer patient-derived xenografts (PDXs), with a take rate of 10-40% and long latency time, multiple groups throughout the world have developed methods for the successful establishment of serially transplantable human prostate cancer PDXs using a variety of immune deficient mice. In 2014, the Movember Foundation launched a Global Action Plan 1 (GAP1) project to support an international collaborative prostate cancer PDX program involving eleven groups. Between these Movember consortium members, a total of 98 authenticated human prostate cancer PDXs were available for characterization. Eighty three of these were derived directly from patient material, and 15 were derived as variants of patient-derived material via serial passage in androgen deprived hosts. A major goal of the Movember GAP1 PDX project was to provide the prostate cancer research community with a summary of both the basic characteristics of the 98 available authenticated serially transplantable human prostate cancer PDX models and the appropriate contact information for collaborations. Herein, we report a summary of these PDX models. Methods: PDX models were established in immunocompromised mice via subcutaneous or subrenal-capsule implantation. Dual-label species (ie, human vs mouse) specific centromere and telomere Fluorescence In Situ Hybridization (FISH) and immuno-histochemical (IHC) staining of tissue microarrays (TMAs) containing replicates of the PDX models were used for characterization of expression of a number of phenotypic markers important for prostate cancer including AR (assessed by IHC and FISH), Ki67, vimentin, RB1, P-Akt, chromogranin A (CgA), p53, ERG, PTEN, PSMA, and epithelial cytokeratins. Results: Within this series of PDX models, the full spectrum of clinical disease stages is represented, including androgen-sensitive and castration-resistant primary and metastatic prostate adenocarcinomas as well as prostate carcinomas with neuroendocrine differentiation. The annotated clinical characteristics of these PDXs were correlated with their marker expression profile. Conclusion: Our results demonstrate the clinical relevance of this series of PDXs as a platform for both basic science studies and therapeutic discovery/drug development. The present report provides the prostate cancer community with a summary of the basic characteristics and a contact information for collaborations using these models.
AB - Background: While it has been challenging to establish prostate cancer patient-derived xenografts (PDXs), with a take rate of 10-40% and long latency time, multiple groups throughout the world have developed methods for the successful establishment of serially transplantable human prostate cancer PDXs using a variety of immune deficient mice. In 2014, the Movember Foundation launched a Global Action Plan 1 (GAP1) project to support an international collaborative prostate cancer PDX program involving eleven groups. Between these Movember consortium members, a total of 98 authenticated human prostate cancer PDXs were available for characterization. Eighty three of these were derived directly from patient material, and 15 were derived as variants of patient-derived material via serial passage in androgen deprived hosts. A major goal of the Movember GAP1 PDX project was to provide the prostate cancer research community with a summary of both the basic characteristics of the 98 available authenticated serially transplantable human prostate cancer PDX models and the appropriate contact information for collaborations. Herein, we report a summary of these PDX models. Methods: PDX models were established in immunocompromised mice via subcutaneous or subrenal-capsule implantation. Dual-label species (ie, human vs mouse) specific centromere and telomere Fluorescence In Situ Hybridization (FISH) and immuno-histochemical (IHC) staining of tissue microarrays (TMAs) containing replicates of the PDX models were used for characterization of expression of a number of phenotypic markers important for prostate cancer including AR (assessed by IHC and FISH), Ki67, vimentin, RB1, P-Akt, chromogranin A (CgA), p53, ERG, PTEN, PSMA, and epithelial cytokeratins. Results: Within this series of PDX models, the full spectrum of clinical disease stages is represented, including androgen-sensitive and castration-resistant primary and metastatic prostate adenocarcinomas as well as prostate carcinomas with neuroendocrine differentiation. The annotated clinical characteristics of these PDXs were correlated with their marker expression profile. Conclusion: Our results demonstrate the clinical relevance of this series of PDXs as a platform for both basic science studies and therapeutic discovery/drug development. The present report provides the prostate cancer community with a summary of the basic characteristics and a contact information for collaborations using these models.
KW - PDX
KW - patient-derived xenograft
KW - prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85052433082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052433082&partnerID=8YFLogxK
U2 - 10.1002/pros.23701
DO - 10.1002/pros.23701
M3 - Article
C2 - 30073676
AN - SCOPUS:85052433082
SN - 0270-4137
VL - 78
SP - 1262
EP - 1282
JO - Prostate
JF - Prostate
IS - 16
ER -